Takenoti offers an intelligence layer for gene editing through a genomic foundation model that predicts optimal guide RNAs, editor proteins, and delivery vectors for therapeutic applications. By leveraging large-scale wet‑lab datasets and high‑throughput NGS validation, the platform reduces experimental trial‑and‑error cycles from years to weeks, enabling biotech and pharma teams to design safe, effective gene‑editing therapies faster and at scale.
Funding
Funding not disclosed
Founders
Product
Problem
Designing therapeutic gene editing interventions currently relies on extensive trial-and-error experiments, leading to long development timelines and high costs. This slows the delivery of potentially life‑saving CRISPR‑based therapies to patients.
Solution
Takenoti provides an intelligence layer for gene editing by offering a genomic foundation model that predicts optimal editing components—including guide RNAs, editor proteins, and delivery vectors—under therapeutic conditions. The platform is trained on proprietary high‑throughput wet‑lab datasets and next‑generation sequencing validation results, enabling rapid in silico design of clinically relevant edits. By converting years of experimental iteration into weeks of computational prediction, the model accelerates the path from target identification to preclinical validation, supporting scalable and reproducible development of gene‑editing medicines.
Target Audience
Primary customers are biotech and pharmaceutical companies, as well as academic research groups, that are developing CRISPR‑based or other genome‑editing therapeutics and need rapid, data‑driven design of editing components.
Features
- Large‑scale, therapeutic‑condition wet‑lab datasets that feed the foundation model with real‑world editing outcomes
- High‑throughput assay integration and NGS‑based validation to continuously improve prediction accuracy
- Automated generation of guide RNAs, editor variants, and delivery context recommendations tailored to specific disease targets
- Predictive scoring of on‑target efficiency and off‑target risk to prioritize safest, most effective designs
- API access for seamless integration into existing biotech pipelines and laboratory information management systems